Salix Pharmaceuticals Ltd (SLXP)

172.81
0.16 0.09
NASDAQ : Health Care
Prev Close 172.65
Open 172.72
Day Low/High 172.71 / 172.96
52 Wk Low/High 86.00 / 172.98
Volume 4.30M
Avg Volume 3.38M
Exchange NASDAQ
Shares Outstanding 64.25M
Market Cap 11.10B
EPS -6.53
P/E Ratio N/A
Div & Yield N.A. (N.A)
Salix Pharmaceuticals Announces 1Q2011 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 1Q2011 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report first quarter 2011 financial results following the close of the U.

Salix Pharmaceuticals Secures Additional Intellectual Property Relating To Rifaximin

Salix Pharmaceuticals Secures Additional Intellectual Property Relating To Rifaximin

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.

Salix Pharmaceuticals Expands Rifaximin Collaboration With Lupin

Salix Pharmaceuticals Expands Rifaximin Collaboration With Lupin

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that as of March 31, 2011 Lupin Ltd.

Salix Reviews The International Liver Congress 2011 Of The European Association For The Study Of The Liver

Salix Reviews The International Liver Congress 2011 Of The European Association For The Study Of The Liver

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that The International Liver Congress™ 2011 of the European Association for the Study of the Liver (EASL) served as the venue for a presentation ...

Salix Pharmaceuticals Ltd. Stock Downgraded (SLXP)

Salix Pharmaceuticals Ltd. Stock Downgraded (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) has been downgraded by TheStreet Ratings from from a buy to hold.

Salix Receives Anticipated FDA Complete Response Letter On XIFAXAN® 550 Mg Tablets Non-C IBS Supplemental New Drug Application

Salix Receives Anticipated FDA Complete Response Letter On XIFAXAN® 550 Mg Tablets Non-C IBS Supplemental New Drug Application

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.

Salix Pharmaceuticals Ltd. Stock Upgraded (SLXP)

Salix Pharmaceuticals Ltd. Stock Upgraded (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) has been upgraded by TheStreet Ratings from a hold to buy.

10 Pharma Stocks With Upside

10 Pharma Stocks With Upside

These pharma stocks are poised for an upside of at least 28%, according to analysts' estimates.

Philip Morris: New Targets, Estimates

Philip Morris: New Targets, Estimates

Philip Morris price target boosted at Citi to $63.50 from $60.50 on potential EPS growth

Salix Pharmaceuticals Reports 4Q2010 And FY2010 Results

Salix Pharmaceuticals Reports 4Q2010 And FY2010 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the fourth quarter and full year ended December 31, 2010.

Salix Rises On Unusually High Volume (SLXP)

Salix Rises On Unusually High Volume (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) is trading at unusually high volume Friday with 3.3 million shares changing hands. It is currently at 4 times its average daily volume and trading up $1.61 (+5.1%).

Sears, E-Trade, Priceline.com Are Big Movers

Sears, E-Trade, Priceline.com Are Big Movers

Sears, E-Trade, Priceline.com are among big market movers Thursday

Salix Stock Falls On Unusually High Volume (SLXP)

Salix Stock Falls On Unusually High Volume (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) is trading at unusually high volume Thursday with 5.3 million shares changing hands. It is currently at 6.7 times its average daily volume and trading down $8.56 (-20.6%).

Salix Stock Gaps Down On Today's Open (SLXP)

Salix Stock Gaps Down On Today's Open (SLXP)

Shares of Salix Pharmaceuticals (Nasdaq:SLXP) were gapping down Thursday morning with an open price 22.1% lower than Wednesday's closing price. The stock closed at $41.45 yesterday and opened today's trading at $32.27.

Salix Anticipates Receipt Of FDA Complete Response Letter On XIFAXAN® 550 Mg Tablets Supplemental New Drug Application

Salix Anticipates Receipt Of FDA Complete Response Letter On XIFAXAN® 550 Mg Tablets Supplemental New Drug Application

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that based on a telephone conversation with the U.

Salix To Host Conference Call To Provide Update Regarding FDA Review Of XIFAXAN® 550 MG Tablets Supplemental New Drug Application

Salix To Host Conference Call To Provide Update Regarding FDA Review Of XIFAXAN® 550 MG Tablets Supplemental New Drug Application

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) will host a conference call at 7:30 a.

Salix Pharmaceuticals To Present At Three Investment Conferences In March

Salix Pharmaceuticals To Present At Three Investment Conferences In March

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at three health care investment conferences during March 2011.

Salix Pharmaceuticals Announces 4Q2010 And FY2010 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 4Q2010 And FY2010 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report fourth quarter 2010 and full year 2010 financial results following the close of the U.

Progenics Pharmaceuticals And Salix Pharmaceuticals Announce Worldwide License Agreement For RELISTOR®

Progenics Pharmaceuticals And Salix Pharmaceuticals Announce Worldwide License Agreement For RELISTOR®

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) and Salix Pharmaceuticals, Ltd.

Salix Pharmaceuticals And Progenics Pharmaceuticals Announce Worldwide License Agreement For RELISTOR®

Salix Pharmaceuticals And Progenics Pharmaceuticals Announce Worldwide License Agreement For RELISTOR®

Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) and Progenics Pharmaceuticals, Inc.

Salix Pharmaceuticals, Inc. And The Colon Cancer Alliance Announce Colonoscopy For Dummies® Is Now Available For Free Download

Salix Pharmaceuticals, Inc. And The Colon Cancer Alliance Announce Colonoscopy For Dummies® Is Now Available For Free Download

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), in partnership with the Colon Cancer Alliance (CCA), is proud to announce the availability of Colonoscopy For Dummies ® .

XIFAXAN® 550 Mg Tablets Demonstrated Significant Acute And Sustained Relief Of Irritable Bowel Syndrome Without Constipation According To Findings Published In The New England Journal Of Medicine

XIFAXAN® 550 Mg Tablets Demonstrated Significant Acute And Sustained Relief Of Irritable Bowel Syndrome Without Constipation According To Findings Published In The New England Journal Of Medicine

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company’s two pivotal Phase 3 efficacy and safety studies of...

Salix Pharmaceuticals To Present At Piper Jaffray Conference

Salix Pharmaceuticals To Present At Piper Jaffray Conference

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the Piper Jaffray 22 nd Annual Healthcare Conference in New York, NY on Tuesday, November 30 at 11:00 a.

Salix Pharmaceuticals Reports 3Q2010 Results

Salix Pharmaceuticals Reports 3Q2010 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2010.

Crofelemer ADVENT Trial Demonstrates Highly Statistically Significant Results In The Treatment Of HIV-Associated Diarrhea

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successful completion and outcome of ADVENT, its pivotal Phase 3 trial, to evaluate the efficacy, safety and tolerability of crofelemer in treating chronic ...

Salix Pharmaceuticals To Present At Credit Suisse Conference

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the Credit Suisse 2010 Healthcare Conference in Phoenix, AZ on Wednesday, November 10 at 3:30 p.

Salix Pharmaceuticals Previews Data Slated For Presentation At 61st Annual Meeting Of The American Association For The Study Of Liver Diseases

Salix Pharmaceuticals, Inc. (NASDAQ:SLXP) today announced that the 61 st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of...

Salix Pharmaceuticals Launches Corporate Twitter Account And Facebook Page

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Company has launched a corporate Twitter account and corporate Facebook page.

Salix Pharmaceuticals Announces 3Q2010 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 3Q2010 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report third quarter 2010 financial results following the close of the U.

Salix Pharmaceuticals Acquires Lumacan™ From Photocure

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has acquired rights to Lumacan™ from Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company.